Table 4.
Univariate analysis outcome in patients with hematological disorders.
| IFS (n = 46) | P | Odds Ratio | 95%CI | ||
|---|---|---|---|---|---|
| Alive (n = 27) | Dead (n = 19) | ||||
| Age | 0.51 | ||||
| ≥ 60 years | 6 | 6 | |||
| < 60 years | 21 | 13 | |||
| Gender | 0.55 | ||||
| Male | 17 | 10 | |||
| Female | 10 | 9 | |||
| Hematological diseases | 0.04 | 5.84 | 1.02-30.56 | ||
| AML | 16 | 17 | |||
| Non-AML* | 11 | 2 | |||
| Disease status | 0.05 | 4.27 | 1.003-18.15 | ||
| Fresh diagnosis/remission | 12 | 3 | |||
| Relapse/refractory | 15 | 16 | |||
| Underlying diabetes mellitus | > 0.99 | ||||
| Yes | 2 | 2 | |||
| No | 25 | 17 | |||
| Chemotherapy intensity | 0.25 | ||||
| Supportive care | 5 | 6 | |||
| Low dose chemotherapy | 3 | 5 | |||
| Standard dose chemotherapy | 16 | 6 | |||
| High dose chemotherapy | 3 | 2 | |||
| Absolute neutrophil count | 0.68 | ||||
| < 500 mm3 < 10 days | 5 | 2 | |||
| < 500 mm3≥10 days | 22 | 17 | |||
| Allogeneic transplantation | 0.68 | ||||
| Yes | 3 | 3 | |||
| No | 24 | 16 | |||
| FESS debridement | 0.10 | 0.27 | 0.064-1.17 | ||
| Yes | 11 | 3 | |||
| No | 16 | 16 | |||
| Fungus type | 0.21 | ||||
| Aspergillosis | 12 | 5 | |||
| Mucormycosis | 2 | 2 | |||
| Others** | 2 | 2 | |||
| Unknown | 10 | 12 | |||
| Invasive image pattern*** | 0.34 | ||||
| Yes | 7 | 8 | |||
| No | 20 | 11 | |||
| Pre-emptive antifungal agent | 0.29 | ||||
| Amphotericin B/ambisome | 15 | 13 | |||
| Caspofungin | 0 | 0 | |||
| Voriconazole | 2 | 0 | |||
| Amphotericin B and caspofungin | 1 | 3 | |||
| Amphotericin B and voriconazole | 7 | 4 | |||
Abbreviation: AML, acute myeloid leukemia; FESS: functional endoscopic sinus surgery.
*Non -AML: including acute lymphoblastic leukemia 6 cases, severe aplastic anemia/myelodysplastic syndrome, 2 cases, other: CLL, 2 cases, CML 1 case
**. Others: Phaeohyphomycosis, Fusarium mycosis, Penicillium mycosis, and unidentified mycosis
***. Invasive image pattern indicates brain abscess, invasion of tissue.